Cargando…
Acute chest syndrome and COVID‐19 in hydroxyurea naïve sickle cell disease patient in a low resource setting
Acute chest syndrome (ACS) is a severe complication of sickle cell disease (SCD) and one of the leading causes of mortality in SCD patients. The management of ACS is challenging and requires prompt intervention to halt clinical deterioration. With the outbreak of the Coronavirus Disease 2019 (COVID‐...
Autores principales: | Mawalla, William Frank, Nasser, Ahlam, Jingu, James Salumu, Joseph, Happiness, Mmbaga, Lilian Gasper, Shija, Eunice, Kakumbula, Helena, Lubuva, Neema Budodi, Meda, Collins, Chamba, Clara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110990/ https://www.ncbi.nlm.nih.gov/pubmed/35602245 http://dx.doi.org/10.1002/jha2.397 |
Ejemplares similares
-
Anaemia in the Hospitalized Elderly in Tanzania: Prevalence, Severity, and Micronutrient Deficiency Status
por: Chamba, Clara, et al.
Publicado: (2021) -
Limited Exchange Transfusion Can Be Very Beneficial in Sickle Cell Anemia with Acute Chest Syndrome: A Case Report from Tanzania
por: Chamba, Clara, et al.
Publicado: (2018) -
Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002) -
Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006) -
Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)